Movement Alert｜Humana Intraday Rise 3.01% in Regular Trading, Supported by Recent Price Target Increases and BlackRock Clinic JV

Market Focus10-20

On October 20, Humana rose 3.01% in Regular Trading, trading at $428.03 per share, with turnover of $112 million.

Recent news flow points to an event-driven setup: multiple brokerages raised their price targets after Humana reported a sharp improvement in Medicare Advantage star ratings, while the company also announced a new joint venture with funds managed by BlackRock's HPS Investment Partners.

In recent days, UBS and Mizuho both lifted their targets to $495, Oppenheimer raised its target to $475, and Barclays increased its target to $582. Earlier this month, Humana said 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027 and reaffirmed full-year adjusted EPS guidance of at least $9. In addition, the new venture will operate nearly 150 CenterWell Senior Primary Care clinics, with additional capital planned over the next two years for clinical operations, new clinics, and acquisitions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment